Skip to main content
MedPathMedPath Home
Clinical Trials/NCT03177174
NCT03177174
Completed
Not Applicable

the General Hospital of PLA

Luo yanrong1 site in 1 country150 target enrollmentJune 12, 2017
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsDrug-Related Side Effects and Adverse Reactions
InterventionsDocetaxelCisplatin
DrugsCisplatinDocetaxel

Overview

Phase
Not Applicable
Intervention
Docetaxel
Conditions
Drug-Related Side Effects and Adverse Reactions
Sponsor
Luo yanrong
Enrollment
150
Locations
1
Primary Endpoint
changes in toxic reaction
Status
Completed
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaArms & InterventionsOutcomesSitesSimilar Trials

Overview

Brief Summary

This study was to evaluate the efficacy ,toxic reaction and safety of different chemotherapy combined with radiotherapy on patients with locally advanced nasopharyngeal carcinoma.

Registry
clinicaltrials.gov
Start Date
June 12, 2017
End Date
February 1, 2020
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Luo yanrong
Responsible Party
Sponsor Investigator
Principal Investigator

Luo yanrong

Clinical Doctor

Chinese PLA General Hospital

Eligibility Criteria

Inclusion Criteria

  • •Patients \> 18, \<70 years old, with locally advanced nasopharyngeal carcinoma.

Exclusion Criteria

  • •patients who had accepted radiotherapy before patients with any ather types of cancer

Arms & Interventions

Docetaxel

Intervention: Docetaxel

Cisplatin

Intervention: Cisplatin

DocetaxelCisplatin

Cisplatin combined with Docetaxel

Intervention: Cisplatin

DocetaxelCisplatin

Cisplatin combined with Docetaxel

Intervention: Docetaxel

Outcomes

Primary Outcomes

changes in toxic reaction

Time Frame: 5 years

incidence rate of the toxic reaction between three groups

Secondary Outcomes

  • over survival(5 years)

Study Sites (1)

Loading locations...

Similar Trials

Not yet recruiting
Phase 1
Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid TumorsRelapsed Pediatric Solid TumorRefractory Pediatric Solid Tumor
NCT03628131Samsung Medical Center46
Completed
Phase 2
Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPCNasopharyngeal Carcinoma
NCT04833257Sun Yat-sen University63
Active, not recruiting
Phase 2
Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M NeuroblastomaNeuroblastoma
NCT03503864Yang Li80
Completed
Phase 3
A phase III randomized study with Paclitaxel (Taxol) and Gemcitabine or Vinorelbine in patients with stage IIIBw - IV non-operable non-small cell lung cancer (NSCLC), performance status (PS) 0,1.
ACTRN12609000946213Hellenic Cooperative Oncology Group441
Active, not recruiting
Phase 3
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal CarcinomaNasopharyngeal Carcinoma
NCT05211232Sun Yat-sen University450